StocksMedium•4 November 2026•
1 min read
Merck & Co. Raises Full-Year 2026 Financial Guidance
Key Facts
1Merck & Co., Inc. revised its full-year 2026 financial outlook, increasing both worldwide sales and non-GAAP EPS guidance.
Merck & Co., Inc. revised its full-year 2026 financial outlook, increasing both its worldwide sales and non-GAAP EPS guidance. Benzinga reported that the update reflects an improvement in the company's financial performance targets for the remainder of the year.
The stock, trading under the ticker MRK, closed at $144.67 on November 3, 2026. During that session, the instrument reached a high of $147.62 and a low of $143.47, as the upward revision suggests robust demand for the company's product portfolio and improved operational efficiencies.